An enlarged prostate is a non-cancerous growth of the prostate gland. Its medical name is benign prostatic hyperplasia, or BPH. The prostate sits below the bladder and wraps around the urethra, the tube that carries urine out of the body. As it grows, it can pinch that tube and make passing urine harder.1
Prostate artery embolization (PAE) treats the prostate through its blood supply, allowing it to shrink without an operation through the urethra. It is usually an outpatient procedure. Whether it is the right choice depends on what is causing the symptoms, how well the bladder works and what matters most to the patient.
An enlarged prostate does not explain every urinary complaint. Some men have a large prostate and few symptoms. Others have only modest enlargement but considerable difficulty passing urine. Prostate size alone does not say how much trouble it is causing.
What it feels like
The symptoms vary from man to man, and they tend to get worse slowly over time. The common ones:1
- A frequent or urgent need to pass urine
- Getting up more often at night to pass urine (nocturia)
- Difficulty starting
- A weak stream, or one that stops and starts
- Dribbling at the end
- A feeling that the bladder has not emptied
Is the prostate the cause?
The diagnosis starts with the symptoms, the medical history and an examination, which may include feeling the prostate with a gloved finger. Tests may include a urine test and a blood test for prostate-specific antigen (PSA).1
A standard questionnaire, the International Prostate Symptom Score (IPSS), scores the symptoms from 0 to 35 and is used again after treatment to measure the change. Other tests measure how strong the urine stream is, how much urine is left in the bladder after passing it, and how large the prostate is, by ultrasound or MRI.2
The score measures the symptoms. It does not establish the diagnosis. A slow stream or urine left in the bladder can come from a blocked outlet, from a bladder that contracts weakly, or from both, so these results are read together with the history and the examination. When it is not clear which is to blame, a pressure-flow study of the bladder can tell them apart.1,2
Other causes of the same symptoms, including bladder problems, infection and prostate cancer, are looked for first, usually by a urologist.1 A treatment that shrinks the prostate cannot be expected to help a man whose trouble comes from his bladder.
BPH is not cancer, and an enlarged prostate does not raise a man’s risk of prostate cancer.3
Treatment
Not every man needs treatment. When the symptoms are mild and do not interfere with life, watching them is reasonable, with a yearly check. Simple changes can help: less to drink in the evening, less caffeine and alcohol, and a review of medicines that make the symptoms worse.1
Medication comes first for most men who need more. Alpha-blockers, such as tamsulosin, relax the muscle in the prostate and the neck of the bladder so that urine flows more easily. Another group of drugs, the 5-alpha-reductase inhibitors such as finasteride and dutasteride, blocks the hormone that drives the prostate’s growth and works more slowly. The two together may work better than either alone.1,4
When medication is not enough, or its side effects are a problem, there are procedures:
- Transurethral resection of the prostate (TURP), an operation through the urethra that cuts away the inner part of the prostate, under spinal or general anesthetic
- Laser therapy, which removes or vaporizes prostate tissue through the urethra; holmium laser enucleation (HoLEP) is one form
- Aquablation, an operation through the urethra that removes prostate tissue with an image-planned waterjet
- Water-vapor treatment, which treats obstructing prostate tissue with the heat of water vapor (steam)
- Prostatic urethral lift (PUL), small implants that hold the prostate away from the urethra
- Prostate artery embolization (PAE), described below
These treatments differ in how much they improve the flow of urine, in the recovery, in their effects on sexual function and in how often another treatment is needed later. Different men put different weight on these things. The urologist brings the whole toolbox. The urologist and the interventional radiologist help a man make a choice that fits his priorities.
Prostate artery embolization
Prostate artery embolization. An artery is reached through a needle puncture in the wrist or the groin, under local anesthetic and sedation. A thin tube (catheter) is guided on live X-ray into the small arteries that feed the prostate. Tiny particles are injected through it. They reduce the blood flow into the prostate, and the gland shrinks. The prostate is treated through its arteries: no instrument is passed through the urethra to remove tissue, and the prostate itself is not cut. The only incision is the puncture in the skin, about 3 millimeters. A man who does not already depend on a urinary catheter usually does not need one, although some men need one for a short time if early swelling blocks the flow. The musing PAE: arterial anatomy and non-target protection uses drawings to show how the prostate’s blood supply varies and what else its arteries can reach.
Who it suits. PAE is not reserved for men who cannot have surgery. It is worth discussing for a man with bothersome symptoms from an enlarged prostate who wants to consider it, including a man who is fit for surgery and prefers its trade-offs. It is especially worth discussing for a man who depends on a catheter, has a large prostate, has concerns about anesthesia or is reluctant to have surgery. A man who takes a blood thinner needs an individual plan.
Where PAE stands. Current American and European urology guidelines include PAE as an option for selected men. A urologist and an interventional radiologist specifically trained in PAE assess whether it suits the patient and plan follow-up together.4,5
What to expect from prostate artery embolization
PAE is generally an outpatient procedure, with no overnight stay. After a period of observation most men go home the same day.
Expect a few days when you may feel worse before you feel better. Pelvic aching, tiredness and a flu-like feeling can last several days. This is called post-embolization syndrome.6 Burning on passing urine, with more frequency and urgency, usually settles over the first week or two. The discomfort is usually eased with over-the-counter anti-inflammatory medicine. There is a small but real chance that early swelling blocks the flow: in a study of 478 men, 2.1% needed a urinary catheter for a time.7
Then the benefit builds. The prostate shrinks over the following weeks. Many men notice an improvement within the first month, the symptoms keep improving for one to three months, and around three months is a good point to judge the result. How soon a man is back to his usual activities depends on his general health and on the work he does.
How PAE compares with TURP
PAE works, it is safe, and it is not a TURP.
The largest published series followed 1,075 men with large prostates. Their median symptom score was 23 before PAE, 6 at six to twelve months and 9 at four to five years.8
PAE can help when medication has not given enough relief. In a randomized trial of men still troubled by symptoms on an alpha-blocker, PAE improved symptoms more than a combination of two drugs.9
In a randomized comparison with TURP, PAE gave men a large improvement in their symptoms, with fewer complications in that trial and no cutting.10,11 TURP did more for the flow of urine and bladder emptying, including at five years.12 The broader evidence about which treatment causes fewer complications is mixed.4
Some men need a second treatment after PAE. The choice depends on the man: what is causing his symptoms, how well his bladder works, the size of his prostate and what matters most to him. When a stronger stream and a bladder that empties more completely are the main goals, an operation that removes tissue may be the better choice.
Common questions
Will it affect sex? Erection, ejaculation, orgasm and fertility are different concerns. In the trial against TURP, erections were on average unchanged after both.10 Ejaculation is usually retained after PAE, although the volume can fall. When the trial’s records were examined again, 40% of men had less ejaculate after PAE and 16% had none; after TURP, 52% had none.13 Compared with TURP, PAE is the better choice for a man who wants to keep ejaculation. It is not a guarantee.
What if a man already has a catheter? PAE does not guarantee freedom from a catheter. A man who already depends on one needs a planned trial of removal after treatment. In the largest published series, 119 of 126 men who depended on a catheter, 94%, were free of it three months after PAE.8 In an international prospective study, 48 of 73 men treated for acute retention, 65.8%, had the catheter removed within three months and remained catheter-free at two years.7
How long does it last? A good early result is not a permanent cure. In one center’s series of 1,072 men, the estimated share needing another procedure, either repeat PAE or surgery, was about one in five by five years and more than half by ten years.14 Not all the men were followed for ten years; these are estimates from one center, not a prediction for an individual. The possibility of another treatment belongs in the conversation from the first visit. The musing After PAE: symptom relief and what follow-up needs to establish explains what happens when symptoms persist or return.
What complications can occur? PAE uses an artery puncture, X-ray contrast and X-rays. Bruising or bleeding at the puncture, infection and a short spell of urinary retention can occur.4,5 Serious complications are uncommon: in the largest series, seven of the 1,075 men, 0.65%, had a severe event, and all recovered without lasting harm.8 Particles reaching an artery outside the prostate can injure the bladder, the rectum or the penis. The risk is reduced by mapping the arteries during the procedure, protecting a branch with a small coil when needed, and stopping when a safe position cannot be found. These steps lower the risk; they do not remove it.
What happens to the PSA blood test? PSA usually rises sharply within a day of PAE, returns toward its previous level by about a month, and may settle lower. The timing varies from man to man.15 A lower PSA does not rule out prostate cancer, and a persistent or newly rising PSA after PAE deserves the same attention as before.16 Finasteride and dutasteride suppress PSA, so stopping one of them changes the number too.16,17 Keep each PSA result with its date, the date of the PAE and any change in prostate medication.
References
- National Institute of Diabetes and Digestive and Kidney Diseases. Enlarged prostate (benign prostatic hyperplasia). NIDDK. Reviewed June 2024. https://www.niddk.nih.gov/health-information/urologic-diseases/prostate-problems/enlarged-prostate-benign-prostatic-hyperplasia
- European Association of Urology. EAU guidelines on the management of non-neurogenic male LUTS: diagnostic evaluation. Uroweb. 2026. https://uroweb.org/guidelines/management-of-non-neurogenic-male-luts/chapter/diagnostic-evaluation
- National Cancer Institute. Understanding prostate changes. Cancer.gov. Updated May 8, 2024. https://www.cancer.gov/types/prostate/understanding-prostate-changes
- European Association of Urology. EAU guidelines on the management of non-neurogenic male LUTS: disease management (section 5.3.4.b). Uroweb. 2026. https://uroweb.org/guidelines/management-of-non-neurogenic-male-luts/chapter/disease-management
- Goueli R, Badlani GH, Welliver C, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline (2026) part III: procedural/surgical management. J Urol. 2026;216(2):161–170. https://doi.org/10.1097/JU.0000000000005099
- Svarc P, Taudorf M, Nielsen MB, Stroomberg HV, Røder MA, Lönn L. Postembolization syndrome after prostatic artery embolization: a systematic review. Diagnostics (Basel). 2020;10(9):659. https://doi.org/10.3390/diagnostics10090659
- Sapoval MR, Bhatia S, Déan C, et al. Two-year outcomes of prostatic artery embolization for symptomatic benign prostatic hyperplasia: an international, multicenter, prospective study. Cardiovasc Intervent Radiol. 2024;47(11):1515–1524. https://doi.org/10.1007/s00270-024-03802-0
- Bhatia S, Bhatia A, Richardson AJ, et al. Prostatic artery embolization: mid- to long-term outcomes in 1,075 patients. J Vasc Interv Radiol. 2025;36(3):456–466. https://doi.org/10.1016/j.jvir.2024.11.002
- Sapoval M, Thiounn N, Descazeaud A, et al. Prostatic artery embolisation versus medical treatment in patients with benign prostatic hyperplasia (PARTEM): a randomised, multicentre, open-label, phase 3, superiority trial. Lancet Reg Health Eur. 2023;31:100672. https://doi.org/10.1016/j.lanepe.2023.100672
- Abt D, Hechelhammer L, Müllhaupt G, et al. Comparison of prostatic artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: randomised, open label, non-inferiority trial. BMJ. 2018;361:k2338. https://doi.org/10.1136/bmj.k2338
- Abt D, Müllhaupt G, Hechelhammer L, et al. Prostatic artery embolisation versus transurethral resection of the prostate for benign prostatic hyperplasia: 2-yr outcomes of a randomised, open-label, single-centre trial. Eur Urol. 2021;80(1):34–42. https://doi.org/10.1016/j.eururo.2021.02.008
- Müllhaupt G, Hechelhammer L, Graf N, et al. Prostatic artery embolisation versus transurethral resection of the prostate for benign prostatic obstruction: 5-year outcomes of a randomised, open-label, noninferiority trial. Eur Urol Focus. 2024;10(5):788–795. https://doi.org/10.1016/j.euf.2024.03.001
- Müllhaupt G, Hechelhammer L, Diener PA, et al. Ejaculatory disorders after prostatic artery embolization: a reassessment of two prospective clinical trials. World J Urol. 2020;38(10):2595–2599. https://doi.org/10.1007/s00345-019-03036-7
- Bilhim T, Costa NV, Torres D, Pinheiro LC, Spaepen E. Long-term outcome of prostatic artery embolization for patients with benign prostatic hyperplasia: single-centre retrospective study in 1072 patients over a 10-year period. Cardiovasc Intervent Radiol. 2022;45(9):1324–1336. https://doi.org/10.1007/s00270-022-03199-8
- Wang MQ, Guo LP, Zhang GD, et al. Prostatic arterial embolization for the treatment of lower urinary tract symptoms due to large (>80 mL) benign prostatic hyperplasia: results of midterm follow-up from Chinese population. BMC Urol. 2015;15:33. https://doi.org/10.1186/s12894-015-0026-5
- National Cancer Institute. Prostate-specific antigen (PSA) test. Cancer.gov. Updated January 31, 2025. https://www.cancer.gov/types/prostate/psa-fact-sheet
- US National Library of Medicine. Finasteride tablets: prescribing information, section 5.1. DailyMed. https://www.dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=32266029-c710-44dd-943f-7e31d0afa622&type=display